- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
ARQL Market Currents
more »
-
May 3 ArQule (ARQL): Q1 EPS of -$0.08 misses by $0.01. Revenue of $8.5M (-36.6% Y/Y) misses by $1.5M. (PR)
Comment![Earnings, Healthcare]
ARQL in Focus
more »
ARQL Related Articles
more »
ARQL News
more »
-
at MarketWatch.com (Jan 17, 2012)
-
at MarketWatch.com (Aug 12, 2010)
-
at MarketWatch.com (Jun 4, 2010)
ARQL Press Releases and Filings
more »
-
Business Wire (May 18, 2012)
-
Business Wire (May 17, 2012)
-
Business Wire (May 3, 2012)
-
Business Wire (Apr 26, 2012)
-
Business Wire (Apr 16, 2012)
ARQL Latest Transcript
more »
ARQL Cramer
more »
Currently, there are no Cramer articles on ARQL.
ARQL Instablog posts
more »
ARQL vs. ETF Alternatives
Company Description
We are a clinical-stage biotechnology company engaged in the research and development of innovative cancer therapeutics. Our mission is to produce novel medicines with differentiated mechanisms of action that target the specific biological pathways implicated in a wide range of cancers. We... More
